CA3144506A1 - Substituted amino heteroaryl derivatives and compositions thereof usefule as antifibrotic compounds - Google Patents
Substituted amino heteroaryl derivatives and compositions thereof usefule as antifibrotic compounds Download PDFInfo
- Publication number
- CA3144506A1 CA3144506A1 CA3144506A CA3144506A CA3144506A1 CA 3144506 A1 CA3144506 A1 CA 3144506A1 CA 3144506 A CA3144506 A CA 3144506A CA 3144506 A CA3144506 A CA 3144506A CA 3144506 A1 CA3144506 A1 CA 3144506A1
- Authority
- CA
- Canada
- Prior art keywords
- 6alkyl
- mmol
- compound according
- nmr
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019902614 | 2019-07-24 | ||
| AU2019902614A AU2019902614A0 (en) | 2019-07-24 | Inhibitor compounds | |
| PCT/AU2020/050763 WO2021012018A1 (en) | 2019-07-24 | 2020-07-24 | Inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3144506A1 true CA3144506A1 (en) | 2021-01-28 |
Family
ID=74192564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3144506A Pending CA3144506A1 (en) | 2019-07-24 | 2020-07-24 | Substituted amino heteroaryl derivatives and compositions thereof usefule as antifibrotic compounds |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12448371B2 (https=) |
| EP (1) | EP4003986A4 (https=) |
| JP (2) | JP2022542140A (https=) |
| KR (1) | KR20220041843A (https=) |
| CN (1) | CN114450281B (https=) |
| AU (1) | AU2020316243A1 (https=) |
| BR (1) | BR112022001270A2 (https=) |
| CA (1) | CA3144506A1 (https=) |
| IL (1) | IL290087B1 (https=) |
| MX (1) | MX2022000845A (https=) |
| WO (1) | WO2021012018A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202213792D0 (en) * | 2022-09-21 | 2022-11-02 | Benevolentai Bio Ltd | New compounds and method |
| US11912675B1 (en) | 2023-10-11 | 2024-02-27 | King Faisal University | N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-3,4-dimethoxybenzimidamide as an antimicrobial compound |
| US11919872B1 (en) | 2023-10-11 | 2024-03-05 | King Faisal University | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
| US11891366B1 (en) | 2023-10-12 | 2024-02-06 | King Faisal University | 4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
| US11999706B1 (en) | 2023-10-13 | 2024-06-04 | King Faisal University | 4-chloro-N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2923661A (en) | 1957-03-22 | 1960-02-02 | Irwin Neisler And Co | N-[2-(1-phenyl-propyl)]-2, 2, 2-trichloroethylidenimine |
| US5684018A (en) | 1994-12-13 | 1997-11-04 | Merck & Co., Inc. | Acyloxyisopropyl carbamates as prodrugs for amine drugs |
| FI982268L (fi) | 1998-10-20 | 2000-04-21 | Tomi Jaervinen | Ei-steroidaalisten anti-inflammatoristen karboksyylihappojen uudet pro drugit, niiden valmistus ja käyttö |
| EP2162427A1 (en) * | 2007-05-22 | 2010-03-17 | Novartis Ag | Benzamides useful as s1p receptor modulators |
| WO2012164103A2 (en) | 2011-06-03 | 2012-12-06 | Universität Zürich | Blockers of the nogo-a s1pr pathway for the treatment of diseases characterized by neuronal damage and lack of subsequent repair |
| US20170165230A1 (en) * | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| AU2015281799B2 (en) * | 2014-06-26 | 2019-11-28 | Central Adelaide Local Health Network Incorporated | Enzyme interacting agents |
| US11135207B2 (en) * | 2016-12-13 | 2021-10-05 | Centaurus Therapeutics | Inhibitors of dihydroceramide desaturase for treating disease |
| CN108079303A (zh) | 2017-12-14 | 2018-05-29 | 广东药科大学 | 鞘氨醇激酶抑制剂在制备治疗肝纤维化药物中的应用 |
-
2020
- 2020-07-24 CA CA3144506A patent/CA3144506A1/en active Pending
- 2020-07-24 AU AU2020316243A patent/AU2020316243A1/en active Pending
- 2020-07-24 WO PCT/AU2020/050763 patent/WO2021012018A1/en not_active Ceased
- 2020-07-24 BR BR112022001270A patent/BR112022001270A2/pt unknown
- 2020-07-24 MX MX2022000845A patent/MX2022000845A/es unknown
- 2020-07-24 US US17/629,218 patent/US12448371B2/en active Active
- 2020-07-24 CN CN202080066385.5A patent/CN114450281B/zh active Active
- 2020-07-24 JP JP2022505207A patent/JP2022542140A/ja active Pending
- 2020-07-24 KR KR1020227003262A patent/KR20220041843A/ko active Pending
- 2020-07-24 EP EP20843975.2A patent/EP4003986A4/en active Pending
-
2022
- 2022-01-24 IL IL290087A patent/IL290087B1/en unknown
-
2025
- 2025-06-16 JP JP2025100363A patent/JP2025134819A/ja active Pending
- 2025-09-08 US US19/322,461 patent/US20260001870A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020316243A1 (en) | 2022-03-03 |
| BR112022001270A2 (pt) | 2022-06-14 |
| CN114450281A (zh) | 2022-05-06 |
| EP4003986A1 (en) | 2022-06-01 |
| IL290087B1 (en) | 2026-01-01 |
| EP4003986A4 (en) | 2023-03-01 |
| US20220274970A1 (en) | 2022-09-01 |
| JP2025134819A (ja) | 2025-09-17 |
| KR20220041843A (ko) | 2022-04-01 |
| WO2021012018A1 (en) | 2021-01-28 |
| US20260001870A1 (en) | 2026-01-01 |
| US12448371B2 (en) | 2025-10-21 |
| IL290087A (en) | 2022-03-01 |
| MX2022000845A (es) | 2022-04-20 |
| JP2022542140A (ja) | 2022-09-29 |
| CN114450281B (zh) | 2024-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3144506A1 (en) | Substituted amino heteroaryl derivatives and compositions thereof usefule as antifibrotic compounds | |
| US12071433B2 (en) | HMOX1 inducers | |
| JP7044769B2 (ja) | Ｕｓｐ３０の阻害剤としての活性を有するシアノ置換複素環 | |
| JP6802251B2 (ja) | 癌の処置のためのｄｕｂ阻害剤としてのシアノピロリジン | |
| US8063084B2 (en) | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | |
| CN110156770B (zh) | 作为tam族激酶抑制剂的氨基吡啶衍生物 | |
| US8163756B2 (en) | Enzyme modulators and treatments | |
| JP5042314B2 (ja) | 慢性骨髄増殖疾患および他の増殖性疾患の治療のために有用なキナーゼ阻害剤 | |
| US9815846B2 (en) | TrkA kinase inhibitors, compositions and methods thereof | |
| KR20170072242A (ko) | 질환의 치료를 위한 헤파란 설페이트 생합성 억제제 | |
| KR20230049675A (ko) | 신규한 옥사디아졸-기반 선택적 hdac6 억제제 | |
| CN101404989A (zh) | 抗菌剂 | |
| AU2019297409B2 (en) | PqsR inverse agonists | |
| JP2019001715A (ja) | 三環性化合物 | |
| CN118696034A (zh) | 作为rad51抑制剂的新型双环化合物 | |
| AU2020264679B2 (en) | Selective ligands of human constitutive androstane receptor | |
| CZ34975U1 (cs) | Ligandy lidského konstitutivního adrostanového receptoru | |
| HK40066338A (zh) | Hmox1诱导剂 | |
| HK40066338B (zh) | Hmox1诱导剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220623 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250212 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250602 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250604 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250714 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250714 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250721 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250721 |